Consequence of the tumor‐associated conversion to cyclin D1b
Abstract Clinical evidence suggests that cyclin D1b, a variant of cyclin D1, is associated with tumor progression and poor outcome. However, the underlying molecular basis was unknown. Here, novel models were created to generate a genetic switch from cyclin D1 to cyclin D1b. Extensive analyses uncov...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2015-03-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.201404242 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849761794420113408 |
|---|---|
| author | Michael A Augello Lisa D Berman‐Booty Richard Carr Akihiro Yoshida Jeffry L Dean Matthew J Schiewer Felix Y Feng Scott A Tomlins Erhe Gao Walter J Koch Jeffrey L Benovic John Alan Diehl Karen E Knudsen |
| author_facet | Michael A Augello Lisa D Berman‐Booty Richard Carr Akihiro Yoshida Jeffry L Dean Matthew J Schiewer Felix Y Feng Scott A Tomlins Erhe Gao Walter J Koch Jeffrey L Benovic John Alan Diehl Karen E Knudsen |
| author_sort | Michael A Augello |
| collection | DOAJ |
| description | Abstract Clinical evidence suggests that cyclin D1b, a variant of cyclin D1, is associated with tumor progression and poor outcome. However, the underlying molecular basis was unknown. Here, novel models were created to generate a genetic switch from cyclin D1 to cyclin D1b. Extensive analyses uncovered overlapping but non‐redundant functions of cyclin D1b compared to cyclin D1 on developmental phenotypes, and illustrated the importance of the transcriptional regulatory functions of cyclin D1b in vivo. Data obtained identify cyclin D1b as an oncogene, wherein cyclin D1b expression under the endogenous promoter induced cellular transformation and further cooperated with known oncogenes to promote tumor growth in vivo. Further molecular interrogation uncovered unexpected links between cyclin D1b and the DNA damage/PARP1 regulatory networks, which could be exploited to suppress cyclin D1b‐driven tumors. Collectively, these data are the first to define the consequence of cyclin D1b expression on normal cellular function, present evidence for cyclin D1b as an oncogene, and provide pre‐clinical evidence of effective methods to thwart growth of cells dependent upon this oncogenic variant. |
| format | Article |
| id | doaj-art-c0a939ceeb9240749fd9c3c0d5d3e22e |
| institution | DOAJ |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2015-03-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-c0a939ceeb9240749fd9c3c0d5d3e22e2025-08-20T03:05:55ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842015-03-017562864710.15252/emmm.201404242Consequence of the tumor‐associated conversion to cyclin D1bMichael A Augello0Lisa D Berman‐Booty1Richard Carr2Akihiro Yoshida3Jeffry L Dean4Matthew J Schiewer5Felix Y Feng6Scott A Tomlins7Erhe Gao8Walter J Koch9Jeffrey L Benovic10John Alan Diehl11Karen E Knudsen12Department of Cancer Biology, Thomas Jefferson UniversityDepartment of Cancer Biology, Thomas Jefferson UniversityKimmel Cancer Center, Thomas Jefferson UniversityMedical University of South CarolinaDepartment of Cancer Biology, Thomas Jefferson UniversityDepartment of Cancer Biology, Thomas Jefferson UniversityMichigan Center for Translational Pathology, University of Michigan Medical CenterMichigan Center for Translational Pathology, University of Michigan Medical CenterPharmacology & Center for Translational MedicinePharmacology & Center for Translational MedicineKimmel Cancer Center, Thomas Jefferson UniversityMedical University of South CarolinaDepartment of Cancer Biology, Thomas Jefferson UniversityAbstract Clinical evidence suggests that cyclin D1b, a variant of cyclin D1, is associated with tumor progression and poor outcome. However, the underlying molecular basis was unknown. Here, novel models were created to generate a genetic switch from cyclin D1 to cyclin D1b. Extensive analyses uncovered overlapping but non‐redundant functions of cyclin D1b compared to cyclin D1 on developmental phenotypes, and illustrated the importance of the transcriptional regulatory functions of cyclin D1b in vivo. Data obtained identify cyclin D1b as an oncogene, wherein cyclin D1b expression under the endogenous promoter induced cellular transformation and further cooperated with known oncogenes to promote tumor growth in vivo. Further molecular interrogation uncovered unexpected links between cyclin D1b and the DNA damage/PARP1 regulatory networks, which could be exploited to suppress cyclin D1b‐driven tumors. Collectively, these data are the first to define the consequence of cyclin D1b expression on normal cellular function, present evidence for cyclin D1b as an oncogene, and provide pre‐clinical evidence of effective methods to thwart growth of cells dependent upon this oncogenic variant.https://doi.org/10.15252/emmm.201404242cell cyclecyclincyclin D1bPARP |
| spellingShingle | Michael A Augello Lisa D Berman‐Booty Richard Carr Akihiro Yoshida Jeffry L Dean Matthew J Schiewer Felix Y Feng Scott A Tomlins Erhe Gao Walter J Koch Jeffrey L Benovic John Alan Diehl Karen E Knudsen Consequence of the tumor‐associated conversion to cyclin D1b EMBO Molecular Medicine cell cycle cyclin cyclin D1b PARP |
| title | Consequence of the tumor‐associated conversion to cyclin D1b |
| title_full | Consequence of the tumor‐associated conversion to cyclin D1b |
| title_fullStr | Consequence of the tumor‐associated conversion to cyclin D1b |
| title_full_unstemmed | Consequence of the tumor‐associated conversion to cyclin D1b |
| title_short | Consequence of the tumor‐associated conversion to cyclin D1b |
| title_sort | consequence of the tumor associated conversion to cyclin d1b |
| topic | cell cycle cyclin cyclin D1b PARP |
| url | https://doi.org/10.15252/emmm.201404242 |
| work_keys_str_mv | AT michaelaaugello consequenceofthetumorassociatedconversiontocyclind1b AT lisadbermanbooty consequenceofthetumorassociatedconversiontocyclind1b AT richardcarr consequenceofthetumorassociatedconversiontocyclind1b AT akihiroyoshida consequenceofthetumorassociatedconversiontocyclind1b AT jeffryldean consequenceofthetumorassociatedconversiontocyclind1b AT matthewjschiewer consequenceofthetumorassociatedconversiontocyclind1b AT felixyfeng consequenceofthetumorassociatedconversiontocyclind1b AT scottatomlins consequenceofthetumorassociatedconversiontocyclind1b AT erhegao consequenceofthetumorassociatedconversiontocyclind1b AT walterjkoch consequenceofthetumorassociatedconversiontocyclind1b AT jeffreylbenovic consequenceofthetumorassociatedconversiontocyclind1b AT johnalandiehl consequenceofthetumorassociatedconversiontocyclind1b AT kareneknudsen consequenceofthetumorassociatedconversiontocyclind1b |